Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Combination Lenvatinib/Pembrolizumab Has Antitumor Activity in Metastatic Clear Cell RCC

September 11th 2017

Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.

Atezolizumab Plus Bevacizumab Shows Encouraging Clinical Activity in mRCC

September 11th 2017

Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.

Pembrolizumab Shows Greater Long-Term Benefits Versus Chemo for Urothelial Carcinoma

September 10th 2017

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Dr. Choueiri on Impact of CABOSUN Results in Renal Cell Carcinoma

September 10th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

Role of PD-L1 Testing in Kidney Cancer

September 8th 2017

Emerging Immunotherapy Combinations in Kidney Cancer

September 8th 2017

Frontline Clinical Trials in Renal Cell Carcinoma

September 8th 2017

RCC: Following Patients on Immunotherapy Vs TKI Therapy

September 8th 2017

Second-Line Decision-Making in Kidney Cancer

September 8th 2017

Defining Progression in Kidney Cancer

September 8th 2017

Frontline Decisions in Metastatic Kidney Cancer

September 8th 2017

RCC: Resection in Metastatic Disease

September 8th 2017

Risk of Postsurgical Disease Recurrence in RCC

September 8th 2017

Recent Data in the Adjuvant Setting of RCC

September 8th 2017

Molecular Profiling in Renal Cell Carcinoma

September 8th 2017

Heterogeneity of Kidney Cancer

September 8th 2017

Dr. Campbell Discusses the Goals of the New RCC Guidelines

September 8th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.

Dr. Choyke on the Importance of Multidisciplinary Care in Prostate Cancer

September 8th 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the importance of multidisciplinary care in prostate cancer.

Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

September 8th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Dr. Gupta on Evolving Treatments for RCC

September 7th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC).